PER® Spectives
PER Spectives
Physicians' Education Resource® (PER®) is committed to advancing patient care through professional education. This podcast is a natural extension of PER®'s efforts to provide medical education for health care providers to stay up to date with advances in medical care, from diagnosis through treatment, with the ultimate goal of improving patient outcomes. Visit http://www.gotoper.com for more information.
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Install for free
Android 5M+ downloads · 4.8 rating
iOS soon
Episodes
S1 Ep8: Part 2 of 5: Top 10 Oncogenic Markers in NSCLC for 2022: An interview with David Gandara MD 17.08.2022 7:48
Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or u...
S1 Ep8: Part 3 of 5: Top 10 Oncogenic Markers in NSCLC for 2022: An interview with Charu Aggarwal MD, MPH 17.08.2022 6:13
Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or u...
S1 Ep8: Part 4 of 5: Top 10 Oncogenic Markers in NSCLC for 2022: An interview with Julia Rotow MD 17.08.2022 17:18
Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or u...
S1 Ep7: Part 5 of 5: Top 10 Oncogenic Markers in NSCLC for 2022: An interview with Balazs Halmos MD, MS 17.08.2022 10:07
Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or u...
S1 Ep6: Tumor Board: Bridging Current Practices and New Therapeutic Developments in ER-Positive Breast Cancer 06.07.2022 49:22
During this educational Tumor Board, breast cancer specialists will showcase challenging scenarios in metastatic and non-metastatic HR+ disease and contextualize data from pivotal clinical trials to optimize decision-making for patients with HR+/HER2- breast cancer. Featuring: Fátima Cardoso, MD Director, Breast Unit Champalimaud Clinical Center Lisbon, Portugal Mario Campone, MD, PhD Chief Execu...
S1 Ep5: Managing Your Patients with CKD 19.04.2022 45:26
Dr. Eden Miller and Kim Zuber, PA-C, discuss the importance of screening patients with chronic kidney disease (CKD) for comorbidities and treating them early. They also discuss the treatment options available among both current and emerging classes of therapies and across different clinical subspecialties. After you listen to this podcast, go to https://www.gotoper.com/2022consckd to learn more an...
S1 Ep4: What You Need to Know About the Evolving Role of TIL Therapy in Cancer Treatment 04.04.2022 23:04
Tumor-infiltrating lymphocyte (TIL) is an emerging therapy that may one day change the approach to the management of solid tumors including melanoma, NSCLC, and more. Join us for a conversation with Dr. Omid Hamid, one of the principal investigators pioneering TIL therapy in clinical trials, as we discuss this novel treatment method. Dr. Hamid will break down what the community physician needs to...
Similar podcasts
Listen to the PER Spectives podcast in Replaio
Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.
